News
Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without ...
Before you offload your codebase to ChatGPT, read this. From security flaws to copyright nightmares, here's what the AI hype machine isn't telling you.
We recently published 10 Resilient Stocks Defying Market Sentiment. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of ...
As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as ...
Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova’s future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, ...
RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.
One computer scientist’s “stunning” proof is the first progress in 50 years on one of the most famous questions in computer ...
The University of Washington's Allen School is rethinking how to train the next generation of software engineers in an ...
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results